FirstWord Group
LightNews LightNews
banner
firstwordgroup.com
FirstWord Group
@firstwordgroup.com
210 followers 35 following 1.3K posts
FirstWord is a global leader in news and intelligence for the Pharma and MedTech industries. Find our services here www.firstwordpharma.com, www.firstwordhealthtech.com, and www.firstwordreports.com
Posts Media Videos Starter Packs
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4h
With new bids in hand, Metsera declares Novo's $10B offer better than Pfizer's $PFE $NVO $MTSR firstwordpharma.com/story/6515530
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4h
Hippocratic AI lands $126M to drive its AI healthcare ambitions
firstwordhealthtech.com/story/6515213
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4h
RevealDx wins MDR clearance for AI-powered lung cancer detection firstwordhealthtech.com/story/6515195
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 6h
Merck & Co. secures $700M from Blackstone to fund work on lead ADC hopeful sac-TMT firstwordpharma.com/story/6515506
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 7h
NEOK Bio debuts with $75M to move ADC duo into the clinic firstwordpharma.com/story/6515504
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 7h
Novo open to Wegovy returning to Hims platform as talks resume firstwordpharma.com/story/6515505
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 9h
TScan trims 30% of staff, prioritising blood cancers programme over solid tumours firstwordpharma.com/story/6515445
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 16h
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial $SRPT firstwordpharma.com/story/6515256
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 20h
Neurocrine nabs ex-China rights to TransThera's NLRP3 portfolio $NBIX firstwordpharma.com/story/6515204
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 20h
UCB gets nod for first therapy in ultra-rare mitochondrial disorder firstwordpharma.com/story/6515226
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 23h
Lilly investing $3B in Netherlands plant that will produce orforglipron $LLY firstwordpharma.com/story/6515179
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 23h
Pfizer escalates fight over Metsera with second lawsuit $PFE $NVO $MTSR firstwordpharma.com/story/6515178
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
Roche turns to Manifold and its AI platform for next-gen brain shuttles firstwordpharma.com/story/6514573
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
AAVantgarde draws $141M series B to advance pair of retinal gene therapies firstwordpharma.com/story/6514544
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
Roche's Gazyva maintains Phase III winning streak with SLE success firstwordpharma.com/story/6514532
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
FDA drug unit chief George Tidmarsh exits amid Aurinia spat firstwordpharma.com/story/6514557
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 3d
Pfizer scores early FTC nod as Metsera tug-of-war with Novo turns legal $PFE $NVO $MTSR firstwordpharma.com/story/6513123
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Otsuka nabs Asia-Pacific rights to 4DMT's retinal gene therapy for $85M $OTSKF $FDMT firstwordpharma.com/story/6512313
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
HRSA welcomes 9 drugs from the likes of J&J, BMS to 340B rebate pilot firstwordpharma.com/story/6512115
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
HIV, liver disease drugs boost Gilead's revenues as cell therapy slips $GILD firstwordpharma.com/story/6512095
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
AstraZeneca details late-stage win for next-gen C5 blocker in gMG $AZN firstwordpharma.com/story/6511991
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Takeda's shares fall as it trims full-year guidance, pipeline $TAK firstwordpharma.com/story/6511695
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
FDA slaps holds on two Intellia studies following liver toxicity signal $NTLA firstwordpharma.com/story/6511140
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
Alnylam raises bar again as Amvuttra keeps beating expectations $ALNY firstwordpharma.com/story/6511138
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
1